drugset / Trial / NCT06785662

Budesonide Irrigation in Allergic Rhinitis

NCT06785662

Phase 4 Not yet recruiting 78 enrolled Siriraj Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Topical nasal steroids are significant therapeutic options for allergic rhinitis (AR). The distribution of intranasal steroid spray (INS) administration is less than that of irrigation. However, the available data on steroid nasal irrigation is limited. This article aims to evaluate the efficacy and adverse effects (AEs) of steroid irrigation in AR patients.

Timeline

Start
2025-02-12
Primary completion
2026-01-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 64 ug Intranasal
Subject Budesonide Small molecule 1 mg Intranasal

Indications